NYT v. FDA's Gottlieb On Drug Approval Standards
Executive Summary
New York Times editorial is critical of approving drugs based on one clinical trial, recommends independent cost benefit analysis.
You may also be interested in...
Gottlieb Uses ASCO Platform To Unveil Two Pilot Programs To Speed Drug Review
US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.
Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency
Existing emergency use authorizations to remain in effect and FDA may continue to issue new ones. Pfizer and Merck are moving to transition Paxlovid and Lagevrio to full approval as FDA allows prescribing without a positive COVID test first.
FDA Urged To Collaborate With USPTO On Orange Book Listings, Eliminate Patent Use Codes
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.